Expression of B2 Receptor on Circulating CD34-Positive Cells and Outcomes of Myocardial Infarction.
Aged
Antigens, CD34
/ metabolism
Biomarkers
/ metabolism
Cells, Cultured
China
/ epidemiology
Female
Follow-Up Studies
Heart Failure
/ epidemiology
Humans
Incidence
Male
Myocardial Infarction
/ complications
Myocardial Revascularization
/ statistics & numerical data
Prognosis
Receptor, Bradykinin B2
/ metabolism
Signal Transduction
Stem Cells
/ metabolism
Survival Rate
Vascular Endothelial Growth Factor A
/ metabolism
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
01
2019
revised:
12
04
2019
accepted:
16
04
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
7
1
2020
Statut:
epublish
Résumé
Bradykinin B2 receptor (B2R) is a widely expressed cell surface receptor. The relationship between B2R expression on circulating CD34+ cells and prognosis of myocardial infarction remains unknown. We analyzed the expression of B2R on circulating CD34-positive cells and plasma VEGF concentration in 174 myocardial infarction patients. All involved patients were divided into two groups: high B2R group and low B2R group according to the median B2R expression percentage. 48 months of follow-up was performed. The endpoints were heart failure and revascularization. The plasma level of VEGF in the low B2R group is 67 ± 12 pg/mL, whereas the high B2R group has significantly elevated VEGF levels of 145 ± 27 pg/mL ( Low expression of B2R on circulating progenitor cells indicated the poor outcomes of myocardial infarction.
Sections du résumé
BACKGROUND
BACKGROUND
Bradykinin B2 receptor (B2R) is a widely expressed cell surface receptor. The relationship between B2R expression on circulating CD34+ cells and prognosis of myocardial infarction remains unknown.
METHODS
METHODS
We analyzed the expression of B2R on circulating CD34-positive cells and plasma VEGF concentration in 174 myocardial infarction patients. All involved patients were divided into two groups: high B2R group and low B2R group according to the median B2R expression percentage. 48 months of follow-up was performed. The endpoints were heart failure and revascularization.
RESULTS
RESULTS
The plasma level of VEGF in the low B2R group is 67 ± 12 pg/mL, whereas the high B2R group has significantly elevated VEGF levels of 145 ± 27 pg/mL (
CONCLUSION
CONCLUSIONS
Low expression of B2R on circulating progenitor cells indicated the poor outcomes of myocardial infarction.
Identifiants
pubmed: 31360266
doi: 10.1155/2019/7816438
pmc: PMC6644252
doi:
Substances chimiques
Antigens, CD34
0
Biomarkers
0
Receptor, Bradykinin B2
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7816438Références
Circulation. 1999 May 4;99(17):2345-57
pubmed: 10226103
J Hypertens. 2000 Feb;18(2):223-8
pubmed: 10694192
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7
pubmed: 10725398
Blood. 2000 May 15;95(10):3106-12
pubmed: 10807776
Circ Res. 2001 Jan 19;88(1):E1
pubmed: 11139484
Circulation. 2001 Feb 6;103(5):634-7
pubmed: 11156872
Circ Res. 2001 Feb 2;88(2):167-74
pubmed: 11157668
J Mol Cell Cardiol. 2001 Sep;33(9):1673-90
pubmed: 11549346
Br J Pharmacol. 2003 Jan;138(1):225-33
pubmed: 12522094
Nat Med. 2003 Jun;9(6):702-12
pubmed: 12778169
Circ Res. 2003 Jul 25;93(2):e17-24
pubmed: 12829619
Circulation. 2004 Oct 5;110(14):2039-46
pubmed: 15451799
Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H202-5
pubmed: 15708952
N Engl J Med. 2005 Sep 8;353(10):999-1007
pubmed: 16148285
J Clin Invest. 2006 May;116(5):1302-9
pubmed: 16604193
Circ Res. 2008 Nov 21;103(11):1335-43
pubmed: 18927465
Hypertension. 2009 Feb;53(2):417-22
pubmed: 19075096
Scand J Clin Lab Invest. 2009;69(6):722-8
pubmed: 19544222
Nature. 2010 May 27;465(7297):483-6
pubmed: 20445537
Circ Res. 2011 Feb 4;108(3):284-93
pubmed: 21164105
Biol Chem. 2013 Mar;394(3):347-51
pubmed: 23152407
Glob Heart. 2012 Dec;7(4):275-95
pubmed: 25689940
Am J Transl Res. 2015 Jul 15;7(7):1214-26
pubmed: 26328006
Oncotarget. 2015 Sep 22;6(28):24675-89
pubmed: 26360782
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
Am J Cardiol. 1983 Feb;51(3):606
pubmed: 6823874
Science. 1997 Feb 14;275(5302):964-7
pubmed: 9020076